In this placebo-controlled , double-blind , @-week , phase @ trial ( ATAMS ) in Australia , Canada , Europe , and the USA , patients aged @-@ years with relapsing multiple sclerosis were randomly assigned via an interactive voice response system in a @:@:@:@ ratio , stratified by geographical region , to receive weekly subcutaneous injections with atacicept ( @ , @ , or @ mg ) or placebo .